Immunology
0 drugs are in development for Multiple Sclerosis (MS) - Relapsing-remitting.
- Companies
- 0
- Clinical trials
- 5
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Multiple Sclerosis (MS) - Relapsing-remitting pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
About this indication
Multiple Sclerosis (MS) - Relapsing-remitting context
Immunology·MeSH: Multiple Sclerosis, Relapsing-Remitting (D020529)
Prevalence
120.0 / 100K
Incidence
7.0 / 100K/yr
Frequently asked questions
How many clinical trials target Multiple Sclerosis (MS) - Relapsing-remitting?
There are 5 clinical trials targeting Multiple Sclerosis (MS) - Relapsing-remitting tracked by BioSniper.
What is the prevalence of Multiple Sclerosis (MS) - Relapsing-remitting?
The estimated prevalence of Multiple Sclerosis (MS) - Relapsing-remitting is approximately 120.0 per 100,000 population.